Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress

May 29, 2024

https://www.prnewswire.com/news-releases/avidity-biosciences-to-present-preliminary-data-from-phase-12-fortitude-trial-of-aoc-1020-in-people-living-with-facioscapulohumeral-muscular-dystrophy-at-31st-annual-fshd-society-international-research-congress-302158556.html

Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.